Lakewood-Amedex announces positive preclinical data for bisphosphocin compounds

LABT•2026-10-07

Lakewood-Amedex Biotherapeutics announced positive preclinical data for its bisphosphocin compounds in urinary tract and pulmonary infection indications. Topline data from its bisphosphocin NU-3 Phase 2a trial are expected in the first quarter of 2027.

Lakewood-Amedex announces positive preclinical data for bisphosphocin compounds

1. Preclinical data

Related News

Clearmind submits recommendations to FDA on future therapeutic use of psychedelic drugs

Avaí Bio, Austrianova hold first steering committee meeting with San Raffaele

Gentex Corporation: UBS cuts target price to $24 from $25

Mint unit Axonex Robotics signs OEM supply and licensing deal with Ireland’s Centridex

Canadian dollar weakens, benchmark yield climbs